Search results
Showing 8116 to 8130 of 8905 results
Ventripoint Medical System Plus for measuring heart volume and function (MIB310)
February 2023: The medtech innovation briefing on Ventripoint Medical System Plus for measuring heart volume and function has been withdrawn as the company have withdrawn from the process.
This medtech innovation briefing has been replaced by NICE healthtech guidance 716.
This medtech innovation briefing has been updated and replaced by NICE healthtech guidance 671.
This medtech innovation briefing has been updated and replaced by NICE's early value assessment guidance on Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies.
The BCM – Body Composition Monitor for managing fluid in people having dialysis (MIB41)
This advice has been updated and replaced by NICE guidance HTG441
EndoPredict gene expression profiling assay for assessing risk of breast cancer recurrence (MIB44)
This advice has been updated and replaced by NICE diagnostics guidance 34.
Flow transcranial direct current stimulation for treating depression (MIB324)
May 2024: This medtech innovation briefing has been withdrawn. This is because the evidence for the technology has changed since it was published. NHS England no longer funds NICE to produce or maintain medtech innovation briefings, so these are no longer being reviewed.
This advice has been updated and replaced by NICE medical technologies guidance 47.
AliveCor Heart Monitor and AliveECG app (Kardia Mobile) for detecting atrial fibrillation (MIB35)
This advice has been updated and replaced by NICE medtech innovation briefing 232.
Lutonix drug-coated balloon for peripheral arterial disease (MIB72)
NICE withdrew this medtech innovation briefing in October 2019 after the MHRA withdrew support for this type of technology being used in intermittent claudication for arterial disease.
This medtech innovation briefing is temporarily unavailable, please contact mibs@nice.org.uk for further information.
FebriDx for C-reactive protein and Myxovirus resistance protein A testing in primary care (MIB114)
This advice has been updated and replaced by NICE medtech innovation briefing 224.
VitalPAC for assessing vital signs of patients in hospital (MIB79)
This advice has been updated and replaced by NICE medtech innovation briefing 205.
This advice has been updated and replaced by NICE medical technologies guidance 42.
Absorb Bioresorbable Vascular Scaffold system for coronary artery disease (MIB84)
NICE withdrew this medtech innovation briefing in November 2017 after the company stopped manufacturing Absorb because of low uptake. Some UK hospitals continue to use the technology in ongoing clinical studies.